Your browser is no longer supported. Please, upgrade your browser.
RIGL Rigel Pharmaceuticals, Inc. weekly Stock Chart
Rigel Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.15 Insider Own0.31% Shs Outstand168.57M Perf Week-0.79%
Market Cap402.73M Forward P/E- EPS next Y-0.29 Insider Trans0.00% Shs Float168.41M Perf Month-39.39%
Income-25.00M PEG- EPS next Q-0.12 Inst Own90.00% Short Float9.10% Perf Quarter38.12%
Sales108.00M P/S3.73 EPS this Y9.00% Inst Trans0.11% Short Ratio1.99 Perf Half Y6.38%
Book/sh0.37 P/B6.76 EPS next Y-20.80% ROA-17.10% Target Price- Perf Year24.38%
Cash/sh0.57 P/C4.35 EPS next 5Y- ROE-37.90% 52W Range1.23 - 5.24 Perf YTD16.82%
Dividend- P/FCF- EPS past 5Y17.40% ROI-108.60% 52W High-52.29% Beta1.42
Dividend %- Quick Ratio3.20 Sales past 5Y48.40% Gross Margin99.10% 52W Low103.25% ATR0.34
Employees163 Current Ratio3.30 Sales Q/Q53.80% Oper. Margin-23.80% RSI (14)50.90 Volatility7.71% 11.16%
OptionableYes Debt/Eq0.31 EPS Q/Q15.40% Profit Margin-23.20% Rel Volume0.38 Prev Close2.54
ShortableYes LT Debt/Eq0.31 EarningsAug 04 AMC Payout- Avg Volume7.68M Price2.50
Recom- SMA20-6.65% SMA5011.15% SMA20019.20% Volume2,882,375 Change-1.57%
Nov-15-19Resumed Cantor Fitzgerald Overweight $7 → $5
Sep-26-19Resumed JP Morgan Overweight $7
Mar-01-19Reiterated Cantor Fitzgerald Overweight $9 → $7
Aug-27-18Initiated Citigroup Buy $8.50
May-02-18Reiterated Cantor Fitzgerald Overweight $6 → $9
Dec-21-17Resumed Piper Jaffray Overweight $6
Dec-15-17Initiated Cantor Fitzgerald Overweight $6
Nov-06-17Resumed H.C. Wainwright Buy $7
Mar-09-17Reiterated H.C. Wainwright Buy $6 → $5
Aug-31-16Reiterated H.C. Wainwright Buy $6 → $7
Aug-30-16Reiterated Piper Jaffray Overweight $10 → $11
Jul-13-16Initiated H.C. Wainwright Buy $6
Jun-13-16Initiated Piper Jaffray Overweight
Apr-22-16Upgrade JP Morgan Neutral → Overweight
Apr-08-13Reiterated Stifel Buy $11 → $7
Nov-29-12Initiated UBS Neutral $9
Nov-06-12Reiterated Oppenheimer Outperform $12 → $15
Mar-26-12Initiated Canaccord Genuity Hold $8
Dec-10-10Downgrade MP Advisors Outperform → Market Perform
Mar-12-10Initiated Piper Jaffray Overweight
Aug-05-20 11:48AM  
Aug-04-20 06:35PM  
Jul-28-20 12:33PM  
Jul-27-20 04:04PM  
Jul-14-20 05:03PM  
Jul-09-20 08:19AM  
Jun-27-20 09:29PM  
Jun-26-20 08:48AM  
Jun-17-20 07:30AM  
Jun-12-20 10:03PM  
Jun-11-20 07:30AM  
Jun-03-20 07:30AM  
May-26-20 07:30AM  
May-08-20 11:03AM  
May-06-20 12:31PM  
May-05-20 06:15PM  
May-01-20 07:30AM  
Apr-28-20 12:33PM  
Apr-27-20 07:30AM  
Apr-11-20 10:20AM  
Mar-24-20 02:19AM  
Mar-12-20 11:02AM  
Mar-03-20 12:56PM  
Feb-27-20 06:05PM  
Feb-20-20 12:31PM  
Feb-11-20 12:14PM  
Jan-13-20 05:03PM  
Jan-10-20 12:54PM  
Jan-09-20 08:40AM  
Dec-18-19 07:23AM  
Dec-17-19 05:00PM  
Dec-11-19 02:44PM  
Nov-19-19 08:40AM  
Nov-18-19 05:34PM  
Nov-15-19 07:30AM  
Nov-13-19 07:30AM  
Nov-08-19 08:00AM  
Nov-07-19 07:30AM  
Nov-06-19 02:32PM  
Nov-05-19 06:05PM  
Oct-29-19 10:32AM  
Oct-23-19 07:30AM  
Oct-22-19 01:04PM  
Oct-18-19 07:30AM  
Oct-16-19 07:30AM  
Oct-14-19 10:28AM  
Oct-02-19 07:00AM  
Sep-23-19 07:30AM  
Sep-20-19 01:33PM  
Sep-15-19 03:28PM  
Aug-28-19 07:30AM  
Aug-16-19 11:26AM  
Aug-10-19 12:04AM  
Aug-06-19 09:24PM  
Aug-02-19 09:06AM  
Jul-30-19 07:30AM  
Jul-09-19 07:56AM  
Jul-01-19 07:15AM  
Jun-27-19 09:50AM  
Jun-23-19 08:54PM  
Jun-13-19 07:30AM  
Jun-12-19 08:15AM  
Jun-05-19 06:42AM  
Jun-03-19 02:38PM  
May-31-19 07:30AM  
May-17-19 09:05AM  
May-16-19 07:30AM  
May-08-19 12:23AM  
May-07-19 06:05PM  
Apr-30-19 07:30AM  
Apr-17-19 03:53PM  
Apr-09-19 08:29PM  
Mar-26-19 07:30AM  
Mar-12-19 12:17PM  
Mar-06-19 12:32AM  
Mar-01-19 09:18AM  
Feb-28-19 04:01PM  
Feb-21-19 07:30AM  
Jan-26-19 11:34AM  
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia. Its clinical programs also comprise R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) program, which is in Phase I clinical study for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is based in South San Francisco, California.